肾移植术后早期基础胰岛素治疗预防移植后糖尿病:多中心随机试验
该开放标签多中心随机试验比较肾移植术后早期基础胰岛素治疗与标准治疗对移植后糖尿病(PTDM)的预防效果。133例干预组接受中效胰岛素,130例对照组接受短效胰岛素。意向治疗人群12个月PTDM率无显著差异(12.2% vs 14.7%),符合方案人群调整后干预组PTDM风险显著降低,但低血糖事件更多。
要点
- 意向治疗分析未显示早期基础胰岛素显著降低12个月PTDM风险。
- 符合方案分析中干预组PTDM风险降低,调整基线差异后显著。
- 干预组低血糖事件显著增多,多为无症状或轻微症状。
核心结论
- 在意向治疗人群中,早期基础胰岛素治疗与标准治疗相比未显著降低12个月PTDM发生率。
- 在符合方案分析中,干预组低血糖发生率更高,但PTDM风险降低,调整基线差异后显著,提示需进一步研究。
研究设计与样本
- 干预组:术后下午血糖≥140 mg/dl时给予中效胰岛素isophane;对照组:空腹血糖≥200 mg/dl时给予短效胰岛素。
主要发现
- 意向治疗人群12个月PTDM率:干预组12.2% vs 对照组14.7%(OR 0.82,95%CI 0.39-1.76);24个月:13.4% vs 17.4%(OR 0.71,95%CI 0.34-1.49)。
- 符合方案人群12个月PTDM OR 0.40(95%CI 0.16-1.01),24个月OR 0.54(95%CI 0.24-1.20)。
- 调整多囊肾病后,符合方案人群12个月PTDM OR 0.21(95%CI 0.07-0.62),24个月OR 0.35(95%CI 0.14-0.87)。
- 干预组低血糖事件显著多于对照组,多为无症状或轻微症状。
- 干预组内不依从胰岛素启动方案与12和24个月PTDM风险显著增高相关。
关键数值与推荐
- PTDM定义:接受抗糖尿病治疗或口服葡萄糖耐量试验2小时血糖≥200 mg/dl。
- 干预触发阈值:术后下午血糖≥140 mg/dl启动中效胰岛素;对照组空腹血糖≥200 mg/dl启动短效胰岛素。
临床怎么用
- 早期基础胰岛素治疗可考虑用于肾移植术后PTDM预防,但需权衡低血糖风险。
- 实施胰岛素启动方案时需关注患者依从性,不依从与PTDM风险增高相关。
局限性
- 意向治疗分析未显示显著差异,主要结论基于符合方案分析,可能受依从性影响。
- 低血糖事件在干预组显著增多,尽管多为无症状或轻微症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-transplantation diabetes mellitus (PTDM) might be preventable. METHODS: This open-label, multicenter randomized trial compared 133 kidney transplant recipients given intermediate-acting insulin isophane for postoperative afternoon glucose ≥140 mg/dl with 130 patients given short-acting insulin for fasting glucose ≥200 mg/dl (control). The primary end point was PTDM (antidiabetic treatment or oral glucose tolerance test-derived 2 hour glucose ≥200 mg/dl) at month 12 post-transplant. RESULTS: In the intention-to-treat population, PTDM rates at 12 months were 12.2% and 14.7% in treatment versus control groups, respectively (odds ratio [OR], 0.82; 95% confidence interval [95% CI], 0.39 to 1.76) and 13.4% versus 17.4%, respectively, at 24 months (OR, 0.71; 95% CI, 0.34 to 1.49). In the per-protocol population, treatment resulted in reduced odds for PTDM at 12 months (OR, 0.40; 95% CI, 0.16 to 1.01) and 24 months (OR, 0.54; 95% CI, 0.24 to 1.20). After adjustment for polycystic kidney disease, per-protocol ORs for PTDM (treatment versus controls) were 0.21 (95% CI, 0.07 to 0.62) at 12 months and 0.35 (95% CI, 0.14 to 0.87) at 24 months. Significantly more hypoglycemic events (mostly asymptomatic or mildly symptomatic) occurred in the treatment group versus the control group. Within the treatment group, nonadherence to the insulin initiation protocol was associated with significantly higher odds for PTDM at months 12 and 24. CONCLUSIONS: At low overt PTDM incidence, the primary end point in the intention-to-treat population did not differ significantly between treatment and control groups. In the per-protocol analysis, early basal insulin therapy resulted in significantly higher hypoglycemia rates but reduced odds for overt PTDM-a significant reduction after adjustment for baseline differences-suggesting the intervention merits further study.Clinical Trial registration number: NCT03507829.
引用
- Schwaiger E, Krenn S, Kurnikowski A, et al. Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial. J Am Soc Nephrol. 2021. PMID: 34330770. doi:10.1681/ASN.2021010127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。